ALDH7A1 and breast cancer: Pharmacologically relevant concentrations of drugs derived from published pharmacokinetic data were utilised (1.15 μM 5-Fluorouracil, 0.1 μM epirubicin, 3 μM docetaxel) for all BC-PDE treatments39–42.